Premium
Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): Combination chemotherapy of advanced esophageal carcinoma
Author(s) -
Gisselbrecht Christian,
Calvo Fabien,
Mignot Laurent,
Pujade Eric,
Bouvry Michel,
Danne Odile,
Belpomme Dominique,
Marty Michel
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830915)52:6<974::aid-cncr2820520607>3.0.co;2-#
Subject(s) - medicine , gastroenterology , chemotherapy , esophagus , fluorouracil , cisplatin , regimen , nephrotoxicity , carcinoma , surgery , toxicity
Twenty‐one patients with advanced epidermoid carcinoma of the esophagus were treated with a combination of 5–fluorouracil (F) 600 mg/m 2 day 1 and day 8; Adriamycin (A) 30 mg/m 2 day 1; and cisplatin (P) 75 mg/m 2 day 1 (FAP) with hydration and mannitol‐induced diuresis. Each course was repeated every 4 weeks. All 21 patients are evaluable for response: 7 patients had an objective response (33%). Two of these responses were complete remissions according to negative endoscopic and pathologic results; five patients had a partial response; all 7 responding patients had metastasis prior to treatment. Median survival of the 21 patients was 8 months. Median survival of 9 months for responders is superior to 4.5 months for nonresponders. No severe myelosuppression or nephrotoxicity was observed. This FAP regimen is useful in the treatment of advanced esophageal tumors.